11:30:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 Ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2019-10-23 12:50:21

Oslo, Norway, 23 October 2019

Reference is made to the stock exchange announcement on 18 October 2019 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 18 October 2019.

The share capital increase pertaining to the 5,511,946 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 1 of the Private Placement (the "Tranche 1 Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 23 October 2019, and the Company's share capital has been increased with NOK 1,102,389.20 through the issuance of the Tranche 1 Shares. The Tranche 1 Shares have been delivered to the investors by way of borrowed shares on 22 October 2019 and the Tranche 1 Shares will be delivered to HealthCap VI L.P. to settle the share loan pursuant to the share lending agreement entered into on 16 October 2019.

Following registration of the share capital increase related to the Tranche 1 Shares in the NRBE, the Company has an issued share capital of NOK 13,228,672.60, divided into 66,143,363 shares, each with a par value of NOK 0.20. Both the share capital increases pertaining to the Private Placement have now been registered in the NRBE.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to the Continuing Obligations for companies listed on the Oslo Stock Exchange section 3.2.